A detailed history of Strs Ohio transactions in Alector, Inc. stock. As of the latest transaction made, Strs Ohio holds 102,600 shares of ALEC stock, worth $503,766. This represents 0.0% of its overall portfolio holdings.

Number of Shares
102,600
Previous 102,600 -0.0%
Holding current value
$503,766
Previous $465,000 3.01%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$4.19 - $6.23 $47,766 - $71,022
11,400 Added 12.5%
102,600 $465,000
Q1 2024

May 13, 2024

BUY
$5.69 - $8.08 $102,420 - $145,440
18,000 Added 24.59%
91,200 $549,000
Q2 2023

Jul 31, 2023

BUY
$5.86 - $7.93 $428,952 - $580,476
73,200 New
73,200 $439,000
Q1 2023

Aug 02, 2023

SELL
$5.85 - $9.84 $33,345 - $56,088
-5,700 Reduced 7.79%
67,500 $417,000
Q4 2022

Jan 26, 2023

SELL
$6.88 - $9.55 $37,152 - $51,570
-5,400 Reduced 7.41%
67,500 $623,000
Q3 2022

Oct 27, 2022

BUY
$8.19 - $13.2 $33,579 - $54,120
4,100 Added 5.96%
72,900 $689,000
Q2 2022

Jul 25, 2022

BUY
$7.65 - $14.24 $58,140 - $108,224
7,600 Added 12.42%
68,800 $699,000
Q1 2022

Apr 21, 2022

BUY
$13.02 - $20.78 $246,078 - $392,742
18,900 Added 44.68%
61,200 $872,000
Q4 2021

Jan 24, 2022

BUY
$19.35 - $25.54 $663,705 - $876,022
34,300 Added 428.75%
42,300 $873,000
Q3 2021

Oct 22, 2021

BUY
$21.65 - $39.49 $173,200 - $315,920
8,000 New
8,000 $182,000
Q3 2020

Dec 14, 2020

SELL
$10.54 - $24.96 $89,590 - $212,160
-8,500 Closed
0 $0
Q2 2020

Jul 23, 2020

BUY
$21.87 - $33.11 $185,895 - $281,435
8,500 New
8,500 $207,000
Q3 2019

Oct 21, 2019

SELL
$14.42 - $22.2 $21,630 - $33,300
-1,500 Closed
0 $0
Q1 2019

Apr 19, 2019

BUY
$15.97 - $22.5 $23,955 - $33,750
1,500 New
1,500 $28,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $405M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Strs Ohio Portfolio

Follow Strs Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.